乳腺癌术前放疗研究进展

doi:10.3760/cma.j.cn371439-20251112-00049

摘要/Abstract

摘要：

术前放疗是乳腺癌综合治疗领域的重要发展方向，其临床价值不仅在于肿瘤降期、提高病理完全缓解率，更在于优化乳房重建时序、降低远期并发症。随着精准放疗及免疫治疗的快速发展，术前放疗在诱导免疫原性死亡、调节肿瘤微环境等方面的生物学增效作用日益受到重视。深入探讨乳腺癌术前放疗的临床价值、关键技术模式及多学科联合策略，系统总结最新证据并梳理关键挑战，可指导乳腺癌患者术前放疗的临床实践，改善患者预后。

关键词: 乳腺肿瘤, 放射疗法, 病理完全缓解

Abstract:

Preoperative radiotherapy is an important development direction in the field of comprehensive treatment of breast cancer. Its clinical value lies not only in tumor downstaging and improving the pathological complete response rate， but also in optimizing the timing of breast reconstruction and reducing long-term complications. With the rapid advancement of precise radiotherapy and immunotherapy， increasing attention has been paid to the biological synergistic effects of preoperative radiotherapy in inducing immunogenic cell death and regulating the tumor microenvironment. This review provides an in-depth discussion of the clinical value， key technical models， and multidisciplinary joint strategies of preoperative radiotherapy for breast cancer， systematically summarizes the latest evidence， and delineates the key challenges， which may guide the clinical practice of preoperative radiotherapy in patients with breast cancer and improve patient prognosis.

Key words: Breast neoplasms, Radiotherapy, Pathological complete response

李丽娜, 刘帅, 张楠. 乳腺癌术前放疗研究进展[J]. 国际肿瘤学杂志, 2026, 53(5): 301-305.

Li Lina, Liu Shuai, Zhang Nan. Research progress on preoperative radiotherapy for breast cancer[J]. Journal of International Oncology, 2026, 53(5): 301-305.

参考文献 30

[1]	Zhang Y, Ji Y, Liu S, et al. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN[J]. J Natl Cancer Cent, 2025, 5(3): 287-296. DOI: 10.1016/j.jncc.2025.02.002.
[2]	Zhu MQ, Yang MD, Zhang JJ, et al. Immunogenic cell death induction by ionizing radiation[J]. Front Immunol, 2021, 12: 705361. DOI: 10.3389/fimmu.2021.705361.
[3]	Wang YJ, Li Y, Yang YX, et al. In situ vaccination caused by diverse irradiation-driven cell death programs[J]. Theranostics, 2024, 14(3): 1147-1167. DOI: 10.7150/thno.86004. pmid: 38323315
[4]	Thiruchelvam PTR, Leff DR, Godden AR, et al. Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study[J]. Lancet Oncol, 2022, 23(5): 682-690. DOI: 10.1016/S1470-2045(22)00145-0. pmid: 35397804
[5]	Yu SWY, Ho CM, Kwok C, et al. Pre-operative radiotherapy for breast cancer patients receiving mastectomy and immediate autologous tissue reconstruction[J]. Eur J Surg Oncol, 2025, 51(8): 110110. DOI: 10.1016/j.ejso.2025.110110.
[6]	Zhang HH, Song DD, Xie LX, et al. Postmastectomy radiotherapy in breast reconstruction: current controversies and trends[J]. Cancer Innov, 2024, 3(1): e104. DOI: 10.1002/cai2.104. pmid: 38948530
[7]	Schaverien MV, Singh P, Smith BD, et al. Premastectomy radiotherapy and immediate breast reconstruction: a randomized clinical trial[J]. JAMA Netw Open, 2024, 7(4): e245217. DOI: 10.1001/jamanetworkopen.2024.5217.
[8]	Schaverien MV, Singh P, Kuerer HM, et al. Comparison of outcomes of microsurgical breast reconstruction after premastectomy and postmastectomy radiation therapy[J]. J Am Coll Surg, 2025, 241(4): 535-549. DOI: 10.1097/XCS.0000000000001444.
[9]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234. DOI: 10.3760/cma.j.cn371439-20231017-00038.
[10]	Wallgren A, Arner O, Bergström J, et al. Preoperative radiotherapy in operable breast cancer: results in the stockholm breast cancer trial[J]. Cancer, 1978, 42(3): 1120-1125. DOI: 10.1002/1097-0142(197809)42:3<1120::aid-cncr2820420313>3.0.co;2-b. pmid: 100202
[11]	Wallgren A, Arner O, Bergström J, et al. Radiation therapy in operable breast cancer: results from the stockholm trial on adjuvant radiotherapy[J]. Int J Radiat Oncol Biol Phys, 1986, 12(4): 533-537. DOI: 10.1016/0360-3016(86)90060-x.
[12]	Riet FG, Fayard F, Arriagada R, et al. Preoperative radiotherapy in breast cancer patients: 32 years of follow-up[J]. Eur J Cancer, 2017, 76: 45-51. DOI: 10.1016/j.ejca.2017.01.022. pmid: 28267657
[13]	Sousa C, Cruz M, Neto A, et al. Neoadjuvant radiotherapy in the approach of locally advanced breast cancer[J]. ESMO Open, 2020, 4(Suppl 2): e000640. DOI: 10.1136/esmoopen-2019-000640.
[14]	McDuff SGR, Stephens SJ, Champ CE, et al. Preoperative partial breast radiation for favorable early-stage breast cancer: a narrative review[J]. Transl Breast Cancer Res, 2025, 6: 17. DOI: 10.21037/tbcr-24-43. pmid: 40421149
[15]	Civil YA, Jonker LW, Groot Koerkamp MPM, et al. Preoperative partial breast irradiation in patients with low-risk breast cancer: a systematic review of literature[J]. Ann Surg Oncol, 2023, 30(6): 3263-3279. DOI: 10.1245/s10434-023-13233-9. pmid: 36869253
[16]	Civil YA, Vasmel JE, Charaghvandi RK, et al. Preoperative magnetic resonance guided single-dose partial breast irradiation: 5-year results of the prospective single-arm ABLATIVE trial[J]. Int J Radiat Oncol Biol Phys, 2025, 121(3): 613-622. DOI: 10.1016/j.ijrobp.2024.07.2326.
[17]	Lavigne D, Hijal T, Vavassis P, et al. Single preoperative radiation therapy with delayed surgery for low-risk breast cancer: oncologic outcome, toxicity and cosmesis of the SPORT-DS phase Ⅰ trial[J]. Radiother Oncol, 2024, 200: 110515. DOI: 10.1016/j.radonc.2024.110515.
[18]	Bosma SCJ, Leij F, Vreeswijk S, et al. Five-year results of the preoperative accelerated partial breast irradiation (PAPBI) trial[J]. Int J Radiat Oncol Biol Phys, 2020, 106(5): 958-967. DOI: 10.1016/j.ijrobp.2019.12.037.
[19]	Bilski M, Konat-Bąska K, Zerella MA, et al. Advances in breast cancer treatment: a systematic review of preoperative stereotactic body radiotherapy (SBRT) for breast cancer[J]. Radiat Oncol, 2024, 19(1): 103. DOI: 10.1186/s13014-024-02497-4. pmid: 39095859
[20]	Bondiau PY, Courdi A, Bahadoran P, et al. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1193-1199. DOI: 10.1016/j.ijrobp.2012.10.034.
[21]	Tiberi D, Vavassis P, Nguyen D, et al. Tumour response 3 months after neoadjuvant single-fraction radiotherapy for low-risk breast cancer[J]. Curr Oncol, 2020, 27(3): 155-158. DOI: 10.3747/co.27.6059. pmid: 32669925
[22]	Reverberi C, Facondo G, Prisco A, et al. Preoperative single fraction stereotactic partial breast irradiation for early-stage breast cancer patients with gammapod technology: pathologic findings and Ki-67 evaluation[J]. Int J Radiat Oncol Biol Phys, 2025, 122(5): 1158-1165. DOI: 10.1016/j.ijrobp.2025.02.012.
[23]	Rahimi AS, Leitch M, Dogan B, et al. Phase Ⅰ pre-operative single fraction dose escalation ablative stereotactic partial breast irradiation (S-PBI) trial for early-stage breast cancer[J]. Int J Radiat Oncol Biol Phys, 2025, 123(1): S125. DOI: 10.1016/j.ijrobp.2025.06.1191.
[24]	Kim J, Fahmy V, Haffty BG. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives[J]. Expert Rev Anticancer Ther, 2024, 24(5): 211-217. DOI: 10.1080/14737140.2024.2333320.
[25]	Semiglazov VF, Topuzov EE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage Ⅱb -Ⅲa breast cancer[J]. Ann Oncol, 1994, 5(7): 591-595. DOI: 10.1093/oxfordjournals.annonc.a058929. pmid: 7993833
[26]	Ben Dhia S, Schiappa R, Gal J, et al. Cyberneo trial investigating the efficacy of stereotactic radiotherapy combined to neoadjuvant chemotherapy for locally advanced breast cancer: 14-years follow-up results[J]. Cancer Radiother, 2025, 29(1): 104592. DOI: 10.1016/j.canrad.2025.104592.
[27]	Vakaet V, Van Hulle H, Van de Vijver K, et al. Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: a randomized pilot trial[J]. Breast, 2022, 62: 10-15. DOI: 10.1016/j.breast.2022.01.010. pmid: 35091184
[28]	De Caluwé A, Bellal S, Cao K, et al. Adapting radiation therapy to immunotherapy: delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase Ⅱ Neo-CheckRay trial[J]. Radiother Oncol, 2025, 206: 110836. DOI: 10.1016/j.radonc.2025.110836.
[29]	Ho AY, Shiao S, Kobald SA, et al. PEARL: a phase Ⅰb/Ⅱ biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2-negative breast cancer[J]. J Clin Oncol, 2024, 42(36): 4282-4293. DOI: 10.1200/JCO.24.00003.
[30]	Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9): 810-821. DOI: 10.1056/NEJMoa1910549.